Gni Group Ltd. · TSE:2160

Gni — Q3 FY2021 Earnings Presentation

12 slides from Gni's earnings presentation, Nov 17, 2021

  1. Slide 1: GNI Group Ltd. Q3 FY2021 Financial Results Corporate Presentation

    Glre v2 ne’ : GNI Group Ltd. Q3 FY2021 Financial Results Corporate Presentation November 17, 2021 Securities Code: 2160

  2. Slide 2: Forward-looking Statements

    Give Forward-looking Statements This presentation contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. (GNI Group). Any statements contained herein that pertain to future operating performance and that are not historic facts are forward-looking statements.

  3. Slide 3: Q3 FY2021 Highlights

    Give Q3 FY2021 Highlights Revenues have increased 37% in the nine-month YTD continuing the strong performance we saw in the first half of 2021 in spite of the Covid pandemic - In China, our Etuary® (Lung Fibrosis therapeutic) drug continues to hold a commanding market share (over 80%) and there is s

  4. Slide 4: Development: Pipeline Update

    We Bring New Hope to Patients GIs Development : Pipeline Update* Product - Indication Phase Ill Etuary® (China) - Connective Tissue Disease Associated Propri > Dual Phase III clinical trials ongoing. Proceeding smoothly Interstitial Lung Disease (CTD-ILD) oprietary (No change from Q2 FY2021) | Radia

  5. Slide 5: Q3 FY2021 Key Developments

    We Bring New Hope to Patients GIss Q3 FY2021 Key Developments v Status of F351 Development - Application to the FDA for Phase II clinical trial in the U.S. is pending. We noted on November 10, the U.S. National Library of Medicine listed Beijing Continent Pharmaceutical Co., Ltd’s planned Phase III

  6. Slide 6: Q3 FY2021 Consolidated Financial Results Comparison (YoY)

    We Bring New Hope to Patients GIss Q3 FY2021 Consolidated Financial Results Comparison (YoY) (Million yen) Statements of Income pas pa Bae aol Change Revenue 6,953 9,536 37.1% Gross profit 5,828 8,327 42.9% Selling, general and administrative expenses 43,495 | 45,503 57.4% Research and A855] A1,417]

  7. Slide 7: Pharmaceutical Segment / Medical Device Segment

    We Bring New Hope to Patients GIss Pharmaceutical Segment Medical Device Segment Revenue and Operating Profit Revenue and Operating Profit 40,000 (Million yen) 2,500 (Million yen) mRevenue mRevenue Operating Profit 8,045 8,064 Operating Profit 8,000 2,000 1,804 1,801 1,728 6,000 5,644 1. s00 1,471 4

  8. Slide 8: Revenue by Region / Operating Profit by Region

    We Bring New Hope to Patients GIs Revenue by Region Operating Profit by Region (Million yen) (million yen) 10,000 2,500 US +» JAPAN US - JAPAN CHINA m= CHINA 8,000 2,000 6,000 1,500 7,911, 4,000 1,000 2,112; 2,000 500 1,830 hood 0 Lea oO 6 Q3 FY2021 Q3 FY2021 FY2017 FY2018 FY2019 FY2020 Cumulative s

  9. Slide 9: SG&A Expenses

    We Bring New Hope to Patients GIs SG&A Expenses (Million yen) pecan eens Change Japan 252 379 51% U.S. 634 911 44% Cullgen 164 448 173% BAB 393 406 3% Others 77 56 -27% China 2,608 4,212 61% BC 2,420 3,925 62% SG 28 38 32% Cullgen Shanghai 45 71 57% Others 113 176 56% Total 3,495 5,503 57% © 2021 GN

  10. Slide 10: R&D Expenses

    We Bring New Hope to Patients GIs R&D Expenses (Million yen) pecan eens Change Japan 15 0 -100% U.S. 174 234 34% Cullgen 120 228 90% Others 54 6 -89% China 665 1,183 78% BC 303 653 115% Cullgen Shanghai 253 470 86% Others 109 59 -46% Total 855 1,417 66% BC : Beijing Continent Pharmaceutical Co., Ltd

  11. Slide 11: FY2021 Financial Forecast — Continued Growth

    We Bring New Hope to Patients GIss FY2021 Financial Forecast — Continued Growth (Revised and disclosed in August 2021) (Million yen) Operating profit} Profit (loss) | Profit/Quarterly |Profit/Quarterly Profit SEUGUIUE (loss) before tax Profit (loss) Se cena FY2021 Forecast 12,753 1,828 1,245 410 1,2

  12. Slide 12: Contact Information

    We Bring New Hope to Patients GIs Contact Information infojapan@gnipharma.com © 2021 GNI Group Ltd. All rights reserved 12

GNI Group — Q3 FY2021 Earnings Presentation on 6ix